New Genetic Risk Report Identifies Hidden Cardiovascular Threats in Patients With Normal Traditional Health Biomarkers

A validated polygenic risk report identifies high cardiovascular risk in healthy-looking patients. Discover how DNA testing is reshaping heart disease prevention.

By: AXL Media

Published: May 1, 2026, 6:17 AM EDT

Source: Information for this report was sourced from News Medical Life Sciences

The Integration of Genomic Data Into Standardized Clinical Preventive Care

Researchers have developed and validated a comprehensive polygenic risk report that provides a holistic view of an individual’s inherited cardiovascular vulnerabilities. Published in the Journal of the American College of Cardiology, the study utilized a massive dataset from the All of Us Research Program and the Mass General Brigham Biobank to track eight specific conditions, including atrial fibrillation, coronary artery disease, and type 2 diabetes. By aggregating thousands of common genetic variants into a single, reliable framework, this platform moves beyond traditional monogenic testing to capture the subtle genetic architecture that defines the risk profile of the general population.

Identifying Extreme Risk Levels for Lipoprotein(a) and Hypercholesterolemia

The most significant finding of the study centered on Lipoprotein(a), a type of cholesterol-carrying particle that is largely determined by genetics rather than lifestyle. The integrated PRS platform revealed that individuals in the top 10% of the high genetic risk category faced a staggering 41-fold increased odds of having elevated Lipoprotein(a) levels compared to those with average genetic risk. Similarly, high-risk individuals showed significantly elevated odds for severe hypercholesterolemia and coronary artery disease. These findings underscore the limitations of relying solely on phenotypic markers like blood pressure, which may remain normal even as underlying genetic factors drive internal damage.

Refining Risk Stratification for Borderline and Intermediate Populations

One of the study’s critical breakthroughs was its ability to improve the accuracy of existing diagnostic tools, such as the Pooled Cohort Equations. When the genetic risk report was added to traditional clinical models, it improved risk classification by 17% for patients previously labeled as "borderline" or "intermediate" risk. This refinement is particularly vital for younger patients under the age of 50, who may not yet exhibit the outward symptoms of heart disease but harbor significant inherited risks. By providing a "net reclassification" of these patients, the report allows clinicians to intervene years before a major cardiac event occurs.